​
​

Travere Therapeutics (TVTX) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChartTranscripts

Travere Therapeutics Revenue Highlights

Latest Revenue (Y)

$145.24M

Latest Revenue (Q)

$62.90M

Main Segment (Y)

License

Travere Therapeutics Revenue by Period

Travere Therapeutics Revenue by Year

DateRevenueChange
2023-12-31--31.50%
2022-12-31--6.80%
2021-12-31-14.71%
2020-12-31-13.11%
2019-12-31-6.75%
2018-12-31-6.01%
2017-12-31-15.98%
2016-12-31-33.74%
2015-12-31-254.19%
2014-12-31-100.00%
2013-12-31-100.00%
2012-12-31-100.00%
2012-02-29-100.00%
2011-02-28-100.00%
2010-02-28-100.00%
2009-02-28--

Travere Therapeutics generated $145.24M in revenue during NA 2023, up -31.50% compared to the previous quarter, and up 88.43% compared to the same period a year ago.

Travere Therapeutics Revenue by Quarter

DateRevenueChange
2024-09-30-16.23%
2024-06-30-30.80%
2024-03-31--8.18%
2023-12-31-21.47%
2023-09-30--37.86%
2023-06-30-4.74%
2023-03-31-2.01%
2022-12-31-4.43%
2022-09-30--1.24%
2022-06-30-11.71%
2022-03-31--15.31%
2021-12-31--16.08%
2021-09-30-24.90%
2021-06-30-15.21%
2021-03-31--7.01%
2020-12-31--0.31%
2020-09-30-5.59%
2020-06-30-1.38%
2020-03-31-2.32%
2019-12-31-5.21%
2019-09-30--0.75%
2019-06-30-12.98%
2019-03-31--9.60%
2018-12-31-7.53%
2018-09-30--1.53%
2018-06-30-7.56%
2018-03-31--8.88%
2017-12-31-4.55%
2017-09-30-3.97%
2017-06-30-15.41%
2017-03-31--9.93%
2016-12-31-9.96%
2016-09-30-1.90%
2016-06-30-14.83%
2016-03-31--4.73%
2015-12-31-8.72%
2015-09-30-16.36%
2015-06-30-38.55%
2015-03-31-23.34%
2014-12-31-68.71%
2014-09-30-45.40%
2014-06-30-20479.69%
2014-03-31-100.00%
2013-12-31-100.00%
2013-09-30-100.00%
2013-06-30-100.00%
2013-03-31-100.00%
2012-11-30-100.00%
2012-08-31-100.00%
2012-05-31-100.00%
2012-02-29-100.00%
2011-11-30-100.00%
2011-08-31-100.00%
2011-05-31-100.00%
2011-02-28-100.00%
2010-11-30-100.00%
2010-08-31-100.00%
2010-05-31--

Travere Therapeutics generated $62.90M in revenue during Q3 2024, up 16.23% compared to the previous quarter, and up 105.36% compared to the same period a year ago.

Travere Therapeutics Revenue Breakdown

Travere Therapeutics Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 23Dec 22Dec 21Dec 20Dec 19
License-----
Active Pharmaceutical Ingredient-----
Bile Acid Products-----
Tiopronin Products-----
Product-----
Thiola License-----

Travere Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 23: License (84.29%), and Active Pharmaceutical Ingredient (15.71%).

Quarterly Revenue by Product

Product/ServiceSep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19
Product--------------------
License--------------------
Active Pharmaceutical Ingredient--------------------
Bile Acid Products--------------------
Tiopronin Products--------------------

Travere Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: Product (96.98%), and License (3.02%).

Travere Therapeutics Revenue Breakdown by Country

Quarterly Revenue by Country

CountryMar 22
FRANCE-

Travere Therapeutics's latest quarterly revenue breakdown by geography, as of Mar 22: FRANCE (100.00%).

Travere Therapeutics Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
APLSApellis Pharmaceuticals--
LEGNLegend Biotech--
TVTXTravere Therapeutics--
PTGXProtagonist Therapeutics--
IDYAIDEAYA Biosciences--
ANABAnaptysBio--
MGTXMeiraGTx--
RVMDRevolution Medicines, Inc. Warrant--
RNAAvidity Biosciences--
STOKStoke Therapeutics--
CYTKCytokinetics--
FIXXQ32 Bio--
KROSKeros Therapeutics--
GPCRStructure Therapeutics--
PCVXVaxcyte--
NUVLNuvalent--
COGTCogent Biosciences--
DICEDICE Therapeutics--
CERECerevel Therapeutics--
VTYXVentyx Biosciences--
AKROAkero Therapeutics--

TVTX Revenue FAQ

What is Travere Therapeutics’s yearly revenue?

Travere Therapeutics's yearly revenue for 2023 was $145.24M, representing a decrease of -31.50% compared to 2022. The company's yearly revenue for 2022 was $212.02M, representing a decrease of -6.80% compared to 2021. TVTX's yearly revenue for 2021 was $227.49M, representing an increase of 14.71% compared to 2020.

What is Travere Therapeutics’s quarterly revenue?

Travere Therapeutics's quarterly revenue for Q3 2024 was $62.9M, a 16.23% increase from the previous quarter (Q2 2024), and a 69.56% increase year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $54.12M, a 30.80% increase from the previous quarter (Q1 2024), and a -9.35% decrease year-over-year (Q2 2023). TVTX's quarterly revenue for Q1 2024 was $41.37M, a -8.18% decrease from the previous quarter (Q4 2023), and a -27.41% decrease year-over-year (Q1 2023).

What is Travere Therapeutics’s revenue growth rate?

Travere Therapeutics's revenue growth rate for the last 3 years (2021-2023) was -36.16%, and for the last 5 years (2019-2023) was -17.17%.

What are Travere Therapeutics’s revenue streams?

Travere Therapeutics's revenue streams in c 23 are License, and Active Pharmaceutical Ingredient. License generated $17.7M in revenue, accounting 84.29% of the company's total revenue Active Pharmaceutical Ingredient generated $3.3M in revenue, accounting 15.71% of the company's total revenue

What is Travere Therapeutics’s main source of revenue?

For the fiscal year ending Dec 23, the largest source of revenue of Travere Therapeutics was License. This segment made a revenue of $17.7M, representing 84.29% of the company's total revenue.